Effect of Hemocare Syrup and tablets in Anemia

Phase 4

Completed

• Conditions: Health Condition 1: D509- Iron deficiency anemia, unspecified

• Registration Number: CTRI/2018/07/014726
• Lead Sponsor: MMC Pharmaceuticals Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2018-09-23
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 219

Inclusion Criteria

Biochemical parameters:

Hb gm%: <12 gm% (female)

Serum iron: <37 μg/dl (female)

TIBC (Total iron-binding capacity): >385 μg/dl

Transferrin saturation: <10%

PCV: <36% (Female)

Exclusion Criteria

Hemoglobin percentage: Below 6 gm%

Pregnant and lactating women.

IDA with cardiac complications, diabetes mellitus, renal disorder, acute and chronic blood loss, bleeding disorders, hemoglobinopathies and malignancy.

IDA in a case of defective absorption like patients of gastrectomy, gastrojejunostomy, sprue syndrome, etc.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in Hb valueTimepoint: 0,15th day, 21st day, 30th day

Secondary Outcome Measures

Name	Time	Method
umber of participants with Adverse Drug Reactions/Adverse Drug EventsTimepoint: 0,15th day, 21st day, 30th day and followed another 1 month